Latest Feature

Masimo's Kiani on 'good-enough innovation,' Medtronic, Apple and 25 years of pus

In this DeviceTalks preview, we catch up with Masimo CEO Joe Kiani to discuss new challenges facing the company and how medtech can break the cycle of the era of 'good-enough' innovation.

Medicare: Medical device companies paid out $200m to physicians last year

Medical device companies' aggregate spend on payment and other gifts to physicians was at least $200 million last year, according to the U.S. Health & Human Services Dept., but critics (and the agency itself) flag widespread problems with the Open Payments database.

Checking on Orange County's medtech climate with OCTANe's Matthew Jenusaitis

Orange County, Calif.'s most-connected man, OCTANe's Matthew Jenusaitis talks to MassDevice.com about OCTANe's 2014 Medical Device Investor Forum.

What's behind the slump in early-stage medtech investment?

Blame the medical device tax and the U.S. regulatory environment for the slump in investment in early-stage medical technologies, Silicon Valley Bank's Ben Johnson tells MassDevice.com.

Kimberly-Clark readies Halyard Health medical device spinout

Halyard Health, the publicly traded, $1.6 billion spinout of Kimberly-Clark's medical device business, is slated to go live in November, soon-to-be COO Chris Lowery tells MassDevice.com.

Subscribe to the MassDevice
Newsletter
Enter your email:

Need Medtech news in a minute? We Deliver!


MassDevice +3,+5 and +7 newsletters get you caught up on all the mission critical news you need in med tech. Sign up today for our free newsletter.

Covidien plans to sell some vascular therapies ahead of Medtronic merger

October 24, 2014 by Brad Perriello

Covidien says it plans to divest its some of its vascular therapies business to mollify U.S. anti-trust regulators about its proposed $43 billion merger with Medtronic.

Covidien plans to sell some vascular therapies ahead of Medtronic merger

MassDevice.com +3 | The top 3 medtech stories for October 24, 2014

October 24, 2014 by MassDevice

Plus 3

Say hello to MassDevice +3, a bite-sized view of the top three medtech stories of the day. This feature of MassDevice.com's coverage highlights our 3 biggest and most influential stories from the day's news to make sure you're up to date on the headlines that continue to shape the medical device industry.

 

Medtech's betting on the GOP in midterm elections

October 24, 2014 by Brian Johnson

A look at the top 10 politicial action committee donations shows that medtech is betting heavily on a GOP win in the midterm elections.

Medtech's betting on the GOP in midterm elections

The medical device industry is betting on a Republican sweep of the U.S. Congress during the 2014 mid term elections, according to a MassDevice.com analysis of donations made by the industry's 10 largest political action committees.

Medtronic updates on $43B Covidien deal financing

October 24, 2014 by Brad Perriello

Medtronic issues an update on the debt financing behind its pending $43 billion acquisition of Covidien.

Medtronic updates on $43B Covidien deal financing

Novo Nordisk receives U.S. subpoena related to Danish factory

October 24, 2014 by MassDevice

The U.S. attorney for Massachusetts subpoenas Novo Nordisk for documents on its plant in Denmark that makes half the world's supply of insulin.

Novo Nordisk receives U.S. subpoena related to Danish factory

(Reuters) - Denmark's Novo Nordisk , the world's biggest maker of insulin, has received a U.S. subpoena requesting documents relating to potential manufacturing issues at its Kalundborg plant in Denmark, the company said on Friday.

Sinopsys Surgical gains $8.3M funding round for sinusitis device | Medtech funding for the week of October 20, 2014

October 24, 2014 by MassDevice

Here's a look at some of the top legal news stories for medical device companies this week: Sinopsys Surgical sniffs up $8.3m for sinusitis device; ZipLine Medical adds $5.7m to Series C round; Medrobotics taps backers for $20m; Sensory Medical raises $1.4m for Relaxis restless legs treatment; Stealth hypertension startup Sympara Medical raises nearly $6m

Sinopsys Surgical sniffs up $8.3m for sinusitis device

October 17, 2014 by Alexander Soule

Report: EndoStim tables IPO

October 24, 2014 by Brad Perriello

EndoStim, which makes an implantable device to treat gastroesophageal reflux disease, reportedly tables its initial public offering due to poor market conditions.

Report: EndoStim tables IPO

EndoStim, citing poor market conditions, has tabled its initial public offering it hoped would raise nearly $36 million for its neurostimulation device for gastroesophageal reflux disease, according to Renaissance Capital.

EndoStim had planned to put $10 million of the IPO's proceeds into clinical studies and another $14 million to commercialize the system.

Built on an AdaptiveTheme using Drupal by Michael Knapp  mknapp